Vitamin D deficiency in multiple myeloma

Matthew M Drake, Alvin C. Ng

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Vitamin D has long been recognized as a fundamental mediator of calcium and skeletal homeostasis. More recently, however, the important role that vitamin D plays in a wide variety of other cellular processes, including inhibition of carcinogenesis by induction of differentiation, inhibition of cellular proliferation and angiogenesis, and promotion of apoptosis, has been appreciated. Multiple myeloma, a severely debilitating, incurable, and uniformly fatal neoplastic disease of B cell origin, is frequently complicated by severe skeletal complications related to lytic bone destruction. The role that vitamin D may play in myeloma bone disease and/or multiple myeloma itself, however, has remained unknown. Here, we review our recent study of 148 subjects who had their vitamin D status determined within 2 weeks of a new clinical diagnosis of multiple myeloma. The prevalence of vitamin D deficiency (defined as a serum 25-hydroxyvitamin D level <20 ng/mL (50 nmol/L)) increased in parallel with International Staging System categorization, indicating that subjects with worse clinical prognosis were more likely to have vitamin D deficiency. However, vitamin D levels were not predictive of skeletal morbidity. These data provide the first data demonstrating an inverse association between vitamin D status and clinical prognosis in patients with multiple myeloma. Further, these data suggest that assessment of vitamin D status may be an important adjunctive aspect of providing care for patients with myeloma, and that larger prospective studies to assess the role of vitamin D in multiple myeloma disease progression, overall survival, and quality of life may be warranted.

Original languageEnglish (US)
JournalEuropean journal of Clinical and Medical Oncology
Volume2
Issue number1
StatePublished - 2010

Fingerprint

Vitamin D Deficiency
Multiple Myeloma
Vitamin D
Bone Diseases
Disease Progression
Patient Care
Carcinogenesis
Homeostasis
B-Lymphocytes
Quality of Life
Cell Proliferation
Prospective Studies
Apoptosis
Calcium
Morbidity
Bone and Bones
Survival
Serum

Keywords

  • Inverse relationship
  • Multiple myeloma
  • Prognosis
  • Skeletal-related events
  • Vitamin D

ASJC Scopus subject areas

  • Oncology

Cite this

Vitamin D deficiency in multiple myeloma. / Drake, Matthew M; Ng, Alvin C.

In: European journal of Clinical and Medical Oncology, Vol. 2, No. 1, 2010.

Research output: Contribution to journalArticle

@article{b981a1a3cf304cdcbb48fe3e0ae1727c,
title = "Vitamin D deficiency in multiple myeloma",
abstract = "Vitamin D has long been recognized as a fundamental mediator of calcium and skeletal homeostasis. More recently, however, the important role that vitamin D plays in a wide variety of other cellular processes, including inhibition of carcinogenesis by induction of differentiation, inhibition of cellular proliferation and angiogenesis, and promotion of apoptosis, has been appreciated. Multiple myeloma, a severely debilitating, incurable, and uniformly fatal neoplastic disease of B cell origin, is frequently complicated by severe skeletal complications related to lytic bone destruction. The role that vitamin D may play in myeloma bone disease and/or multiple myeloma itself, however, has remained unknown. Here, we review our recent study of 148 subjects who had their vitamin D status determined within 2 weeks of a new clinical diagnosis of multiple myeloma. The prevalence of vitamin D deficiency (defined as a serum 25-hydroxyvitamin D level <20 ng/mL (50 nmol/L)) increased in parallel with International Staging System categorization, indicating that subjects with worse clinical prognosis were more likely to have vitamin D deficiency. However, vitamin D levels were not predictive of skeletal morbidity. These data provide the first data demonstrating an inverse association between vitamin D status and clinical prognosis in patients with multiple myeloma. Further, these data suggest that assessment of vitamin D status may be an important adjunctive aspect of providing care for patients with myeloma, and that larger prospective studies to assess the role of vitamin D in multiple myeloma disease progression, overall survival, and quality of life may be warranted.",
keywords = "Inverse relationship, Multiple myeloma, Prognosis, Skeletal-related events, Vitamin D",
author = "Drake, {Matthew M} and Ng, {Alvin C.}",
year = "2010",
language = "English (US)",
volume = "2",
journal = "European journal of Clinical and Medical Oncology",
issn = "1759-8958",
publisher = "San Lucas Medical",
number = "1",

}

TY - JOUR

T1 - Vitamin D deficiency in multiple myeloma

AU - Drake, Matthew M

AU - Ng, Alvin C.

PY - 2010

Y1 - 2010

N2 - Vitamin D has long been recognized as a fundamental mediator of calcium and skeletal homeostasis. More recently, however, the important role that vitamin D plays in a wide variety of other cellular processes, including inhibition of carcinogenesis by induction of differentiation, inhibition of cellular proliferation and angiogenesis, and promotion of apoptosis, has been appreciated. Multiple myeloma, a severely debilitating, incurable, and uniformly fatal neoplastic disease of B cell origin, is frequently complicated by severe skeletal complications related to lytic bone destruction. The role that vitamin D may play in myeloma bone disease and/or multiple myeloma itself, however, has remained unknown. Here, we review our recent study of 148 subjects who had their vitamin D status determined within 2 weeks of a new clinical diagnosis of multiple myeloma. The prevalence of vitamin D deficiency (defined as a serum 25-hydroxyvitamin D level <20 ng/mL (50 nmol/L)) increased in parallel with International Staging System categorization, indicating that subjects with worse clinical prognosis were more likely to have vitamin D deficiency. However, vitamin D levels were not predictive of skeletal morbidity. These data provide the first data demonstrating an inverse association between vitamin D status and clinical prognosis in patients with multiple myeloma. Further, these data suggest that assessment of vitamin D status may be an important adjunctive aspect of providing care for patients with myeloma, and that larger prospective studies to assess the role of vitamin D in multiple myeloma disease progression, overall survival, and quality of life may be warranted.

AB - Vitamin D has long been recognized as a fundamental mediator of calcium and skeletal homeostasis. More recently, however, the important role that vitamin D plays in a wide variety of other cellular processes, including inhibition of carcinogenesis by induction of differentiation, inhibition of cellular proliferation and angiogenesis, and promotion of apoptosis, has been appreciated. Multiple myeloma, a severely debilitating, incurable, and uniformly fatal neoplastic disease of B cell origin, is frequently complicated by severe skeletal complications related to lytic bone destruction. The role that vitamin D may play in myeloma bone disease and/or multiple myeloma itself, however, has remained unknown. Here, we review our recent study of 148 subjects who had their vitamin D status determined within 2 weeks of a new clinical diagnosis of multiple myeloma. The prevalence of vitamin D deficiency (defined as a serum 25-hydroxyvitamin D level <20 ng/mL (50 nmol/L)) increased in parallel with International Staging System categorization, indicating that subjects with worse clinical prognosis were more likely to have vitamin D deficiency. However, vitamin D levels were not predictive of skeletal morbidity. These data provide the first data demonstrating an inverse association between vitamin D status and clinical prognosis in patients with multiple myeloma. Further, these data suggest that assessment of vitamin D status may be an important adjunctive aspect of providing care for patients with myeloma, and that larger prospective studies to assess the role of vitamin D in multiple myeloma disease progression, overall survival, and quality of life may be warranted.

KW - Inverse relationship

KW - Multiple myeloma

KW - Prognosis

KW - Skeletal-related events

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=77956291647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956291647&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77956291647

VL - 2

JO - European journal of Clinical and Medical Oncology

JF - European journal of Clinical and Medical Oncology

SN - 1759-8958

IS - 1

ER -